10-Q: Hyperfine Q3 2025: Sales Decline, Losses Mount, Capital Raised

Hyperfine, Inc. reports a Q3 2025 net loss of $11.0 million on declining sales, while securing $18.4 million in net proceeds from an October 2025 public offering.

Summary

• Net loss for the three months ended September 30, 2025, was $11.0 million, an increase from $10.3 million in the same period of 2024.
• Total sales for Q3 2025 decreased by 5.7% to $3.4 million from $3.6 million in Q3 2024.
• Device sales for Q3 2025 decreased by 4.7% to $2.9 million from $3.0 million in Q3 2024, primarily due to a decrease in units sold (8 units in Q3 2025 vs. 13 units in Q3 2024).
• Service sales for Q3 2025 decreased by 10.5% to $0.5 million from $0.6 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $29.7 million, a slight decrease from $30.3 million in the same period of 2024.
• Total sales for the nine months ended September 30, 2025, decreased by 21.8% to $8.3 million from $10.6 million in the same period of 2024.
• Total Swoop system units sold were 8 units for Q3 2025 (vs. 13 in Q3 2024) and 22 units for the nine months ended September 30, 2025 (vs. 39 in the same period of 2024).
• Research and development expenses decreased by 31.0% in Q3 2025 to $4.0 million, primarily due to lower headcount, consulting, and outsourcing expenses.
• General and administrative expenses decreased by 7.9% in Q3 2025 to $4.2 million, mainly due to lower stock-based compensation and headcount costs.
• Sales and marketing expenses increased by 2.9% in Q3 2025 to $2.6 million, driven by increased travel and other expenses.
• Cash and cash equivalents were $21.6 million as of September 30, 2025, down from $37.6 million at December 31, 2024.
• The company completed an October 2025 public offering, raising approximately $18.4 million in net proceeds.
• Accumulated deficit reached $324.1 million as of September 30, 2025.
• Received 510(k) clearance from the FDA in May 2025 for its tenth-generation AI-powered software, Optive AI, and for the new next-generation Swoop system.
• Received CE Mark and UKCA Mark approvals for Optive AI software in August 2025.

Sentiment

Score: 3

Explanation: The company continues to experience significant sales declines and increasing net losses, leading to substantial cash burn and requiring frequent capital raises. While product innovation and regulatory clearances are positive, the financial performance indicates ongoing challenges to achieve profitability and sustain operations without further dilution.

Positives

• Net loss for the nine months ended September 30, 2025, decreased slightly to $29.7 million from $30.3 million in the prior year.
• Research and development expenses decreased by 31.0% in Q3 2025 and 21.7% for the nine months, reflecting cost management.
• General and administrative expenses decreased by 7.9% in Q3 2025 and 8.5% for the nine months.
• Successful FDA 510(k) clearance in May 2025 for the tenth-generation AI-powered Optive AI software and the new next-generation Swoop system, featuring new hardware and improved image quality/acquisition times.
• Obtained CE Mark and UKCA Mark approvals for Optive AI software in August 2025, enabling broader European commercial expansion.
• Secured significant grant funding from the Bill & Melinda Gates Foundation for neurodevelopment research in low-to-middle income countries.
• Successfully raised approximately $18.4 million in net proceeds from an October 2025 public offering, improving liquidity.

Negatives

• Total sales decreased by 5.7% in Q3 2025 and 21.8% for the nine months ended September 30, 2025, compared to the prior year periods.
• Device sales decreased by 4.7% in Q3 2025 and 24.9% for the nine months, primarily due to a decrease in units sold (8 units in Q3 2025 vs. 13 in Q3 2024; 22 units for nine months 2025 vs. 39 in nine months 2024).
• Net loss increased for the three months ended September 30, 2025, to $11.0 million from $10.3 million in the prior year.
• Cash and cash equivalents significantly decreased to $21.6 million as of September 30, 2025, from $37.6 million at December 31, 2024.
• Accumulated deficit grew to $324.1 million as of September 30, 2025.
• Interest income decreased significantly by 68.0% in Q3 2025 and 63.9% for the nine months, due to lower cash balances.
• A loss of $2.3 million in Q3 2025 and $0.6 million for the nine months due to changes in the fair value of warrant liabilities.
• The company has a history of negative working capital and recurring net losses, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Reliance on a single source manufacturer and single source suppliers for products.

Risks

• History of losses and ability to continue as a going concern without generating sufficient revenue and positive operating cash flows.
• Reliance on a single source manufacturer and single source suppliers for products, which could negatively impact business if disrupted.
• Uncertainty caused by geopolitical and macroeconomic impacts, including conflicts, inflation, and tariffs.
• Ability to obtain additional financing on acceptable terms or at all, which could lead to delays or abandonment of development/commercialization programs.
• Potential dilution for stockholders if additional funds are raised by issuing equity or equity-linked securities.
• Future debt financing may involve covenants restricting operations.
• Inability to fully offset higher costs from inflationary pressures through price increases.
• Exposure to foreign exchange risk, though currently limited.

Future Outlook

The company expects to continue incurring negative cash flows from operations and recurring net losses for the foreseeable future until product and service sales generate sufficient gross profit to cover operating expenses. Existing cash and cash equivalents, including net proceeds from the October 2025 Offering, are expected to fund operations for at least the next 12 months. Future cash requirements depend on market adoption, sales and marketing expansion, research and development costs, collaborations, potential future regulatory clearances or approvals for products, and the effect of competing technological and market developments.

Management Comments

• We are an innovative health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging.
• We believe our market opportunity is significant across the multiple sites of care where the Swoop system brings clinical and economic value. We estimate in the United States alone that our total addressable market for Swoop system device placements is more than $16 billion.
• The Swoop system is the first FDA-cleared, portable, ULF, MR brain imaging system that is capable of providing imaging at multiple sites of care, such as intensive care units, clinics, emergency departments or physicians offices, and can inform the timely detection, diagnosis, monitoring, and treatment of acute and chronic neurological conditions inside and outside the hospital.
• As we move forward, we are continuously investing in improving our AI-powered image quality and leveraging each imaging-focused software release to further improve the Swoop system performance.
• Management believes the net proceeds from the recent offering described under Note 15 Subsequent Events and the Company's anticipated revenue, provides an opportunity to continue as a going concern.

Industry Context

The demand for MR imaging is increasing due to an aging population and rising prevalence of neurological, neurodegenerative, and cardiovascular conditions, alongside trends towards decentralized healthcare. The Swoop system addresses the limitations of conventional MRI (cost, facilities, specialized operators) by offering a portable, ULF, AI-powered solution, aiming to increase access to MRI in various care settings, including lowand middle-income countries.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. It focuses on the company's internal performance and market opportunity.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Utilizes and subleases office and lab space from 4Catalyzer Corporation (4C), a related party, paying approximately $161,000 in Q3 2025 and $364,000 for the nine months ended September 30, 2025.
• Engages 4C for services under a Master Services Agreement, paying $32,000 in Q3 2025 and $90,000 for the nine months ended September 30, 2025.
• As of September 30, 2025, $45,000 was due to 4C for expenses paid on the company's behalf.

Stakeholder Impact

• Shareholders: Significant dilution from recent and ongoing equity offerings (February 2025, October 2025, ATM program) due to continued losses and capital needs. The accumulated deficit continues to grow.
• Employees: Decreased salary and benefits due to lower headcount in R&D and G&A, potentially impacting morale or talent retention. Stock-based compensation is a component of overall compensation.
• Customers: Continued product innovation (Optive AI, next-gen Swoop system) and international expansion efforts aim to improve product offerings and accessibility.
• Creditors: The company's "going concern" warning and reliance on future financing indicate higher risk for creditors.
• Suppliers: Reliance on single-source manufacturers and suppliers poses a risk to supply chain stability.

Next Steps

• Continue investing in improving AI-powered image quality and leveraging imaging-focused software releases to enhance Swoop system performance.
• Develop new imaging applications to broaden the range of clinical uses for proprietary technology.
• Explore the Swoop system's role as a brain imaging clinical decision support platform using AI and cloud technology.
• Expand commercial focus beyond critical care into hospital emergency departments, hospital-based neurology clinics, and outside the hospital in neurology offices.
• Execute on a global expansion strategy, broadening access to MR brain imaging in regions with large populations, low MRI penetration, and unmet healthcare needs.
• Continue to develop a scalable approach to measuring neurodevelopment via ULF brain imaging in neonates, infants, and young children in low-to-middle income countries through February 2026, supported by BMGF grant.

Key Dates

Recommendation

The company exhibits significant financial distress with declining sales, increasing net losses, and substantial cash burn. The repeated need for capital raises, including a recent $18.4 million offering, indicates a precarious liquidity position and leads to significant shareholder dilution. While product innovation and regulatory clearances are positive, they have not yet translated into sustainable revenue growth or profitability. The "going concern" warning, coupled with reliance on single-source suppliers and a growing accumulated deficit, suggests high operational and financial risk. A seasoned investor would likely view the current financial trajectory as unsustainable without a clear path to profitability, making the stock a high-risk investment with a strong potential for further value erosion.

Keywords

portable MRI, ultra-low-field MRI, ULF MR, AI-powered imaging, medical devices, brain imaging, healthcare technology, FDA clearance, Optive AI, Hyperfine, HYPR, Q3 2025 earnings, medical diagnostics